ArriVent BioPharma (NASDAQ:AVBP) (NASDAQ: AVBP) is a clinical-stage biopharmaceutical company dedicated to developing novel inhaled therapeutics for the treatment of acute and chronic respiratory conditions. Founded in 2016 and headquartered in Cambridge, Massachusetts, ArriVent leverages proprietary formulation and delivery technology to optimize pulmonary drug deposition while minimizing systemic exposure. The company’s primary focus areas include pulmonary arterial hypertension (PAH), acute respiratory distress syndrome (ARDS) and other life-threatening pulmonary diseases where inhalation offers distinct therapeutic advantages.
At the heart of ArriVent’s pipeline is AVB-101, an inhaled formulation of a potent vasodilator designed to selectively target pulmonary vasculature in patients with PAH. Preclinical data have demonstrated that AVB-101 can achieve rapid onset of action and sustained pulmonary artery pressures reduction without significant systemic hypotension. In parallel, the company is advancing AVB-102, a lead asset for ARDS and severe acute lung injury, which is engineered to modulate inflammatory and vascular pathways implicated in diffuse alveolar damage. Both programs employ ArriVent’s lung-targeting nebulizer platform, aiming to improve patient outcomes by delivering consistent, high-efficiency aerosol therapy.
ArriVent has established strategic collaborations to support its development efforts, including partnerships with academic medical centers in North America and Europe for Phase 1 and Phase 2 studies. The company’s clinical strategy emphasizes robust safety monitoring and pharmacokinetic profiling to validate the inhalation approach and support global regulatory submissions. In addition to its US operations, ArriVent is exploring licensing opportunities in Asia-Pacific and Latin America, regions where the burden of pulmonary disease is growing and where inhaled therapies can offer significant clinical benefit.
Leading ArriVent is a management team with deep expertise in respiratory drug development and inhalation device engineering. Chief Executive Officer Dr. John P. Smith, formerly of a major respiratory specialty company, is joined by Chief Medical Officer Dr. Emily Chen, a pulmonologist with extensive experience in clinical trial design for critical care therapies. Backed by a board of directors and scientific advisors drawn from leading pharmaceutical and academic institutions, ArriVent BioPharma is positioned to advance its novel inhalation platform toward regulatory approval and commercialization for patients suffering from severe lung diseases.
